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 The main objective of this appendix is to provide further details with regard to the 
methods and results presented in the main text. In particular, we present additional information 
on the population-level model as well as supplementary sensitivity analysis results. 
 
SUPPLEMENTARY METHODS 
 
Choice of Strategies 
 
A number of public health responses have been implemented in settings with limited 
resources to treat HIV. These include: later treatment initiation, use of standardized treatment 
regimens, restricted number of recommended regimens, use of less expensive but potentially 
more toxic drugs, and less frequent and/or less expensive monitoring of disease progression [1]. 
One policy response receiving little consideration is ART discontinuation after treatment failure. 
World Health Organization (WHO) guidelines have recommended continuing treatment in 
patients who fail the last available regimen [1]. However, some have suggested a discontinuation 
policy could be considered by decision makers in resource-limited settings to increase treatment 
access [2].  
 
Individual-level Model 
 
 The individual-level model (i.e., the CEPAC-International model) has been well-
described [3-9]. Additional details regarding the model ― including the model flow chart 
depicting how hypothetical patients transition through model health states, as well as the 
mathematical equations used to represent transitions between model health states ― are available 
at http://web2.research.partners.org/cepac.  
 
Population-level Model 
 
Linear programming model 
 
 The linear programming model is specified formally in Equation A1, below. 
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  where c = index for incident HIV-infected 
cohorts that have been detected and 
diagnosed (c=1,..., q) 
i = index for m mutually exclusive 
treatment strategies (i=0,…, m) 
yc,i = life expectancy of persons from 
incident cohort c and receiving 
treatment strategy i  
fc,i = proportion of individuals from 
incident cohort c and receiving 
treatment strategy i 
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where 
 
p = index of time periods (p=1, …, q) 
πn,c,i = proportion receiving treatment 
in year n=p–c after detection among 
persons in incident cohort c who are 
assigned to treatment strategy i 
dc = number of HIV-infected 
individuals in incident cohort c  
xp = number of available treatment 
slots in period p 
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The population-level, linear programming model consists of the objective function 
(Equation A1), which seeks to maximize accumulated life-years for multiple cohorts of newly-
detected, HIV infected individuals, including those who are not treated; a treatment capacity 
constraint ensuring that the number of available treatment “slots” in each period is not exceeded 
by the number of people on active treatment (Equation A1.a); a non-negativity constraint 
(Equation A1.b) ensuring that implemented levels of each strategy do not fall below 0%; and an 
implementation constraint (Equation A1.c) ensuring that the sum of the proportion of persons 
assigned to strategies within each period does not exceed 100%. For the steady state analysis, we 
assume that dc=d and xp=x, where d and x are constants (Equation A1.a).  
 
The population-level analysis was implemented in Microsoft Excel using Solver 
(Frontline Systems) software, which relies on the simplex method [10, 11].  
 
Linear programming model framework 
 
We choose to employ a mathematical programming model not only to provide 
information on optimal implementation of alternative treatment strategies but also to do so by 
explicitly accounting for treatment-related resource constraints [11, 12]. The method also holds 
the capability of implementing mixed solutions (i.e., partial implementation of 2 or more 
strategies) [13, 14]. We chose to employ a particular class of mathematical programming models, 
the linear programming model, although we explored the option of employing an integer 
programming model. In Equation 1a, the decision variable (fi), which represents the fraction of 
individuals receiving each treatment strategy, is multiplied by the number of patients seeking 
treatment (d). This multiplication could lead to fractional numbers of patients receiving 
treatment. Because individuals are not technically divisible, this suggests use of an integer 
programming model. However, given the computational complexities associated with solving 
integer programming problems and given large population sizes, the errors introduced by 
ignoring this integer constraint are likely to be small [15]. Therefore, we chose a linear 
programming model for its computational effectiveness and efficiency. 
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Modeling of treatment capacity 
 
In developing and specifying the model, we chose to model the treatment capacity 
constraint in terms of treatment slots, defined in terms of numbers of individuals receiving ART 
annually. Treatment slots were chosen as a proxy for the myriad constraints faced by public 
sector antiretroviral programs, including financing, human resource capacity, health and social 
service constraints, and drug, technology, and personnel affordability [16-18]. While recent HIV-
related studies have modeled explicitly only funding constraints [19-21], we believe that 
financing reflects only one dimension of treatment capacity constraints. Therefore, we chose to 
characterize treatment capacity in terms of a single metric, available treatment “slots”, which are 
limited based on a variety of factors.  
 
Input parameters 
 
The individual-level model produced several projections that were used as inputs to the 
population-level model. These included: (1) strategy-specific life expectancy estimates for the 
objective function parameter yc,i (Equation A1), and (2) the number receiving ART annually, 
which was used to derive strategy-specific annual probability of receiving ART (πn,c,i in Equation 
A1.a) and cohort and strategy-specific annual treatment need (i.e., πn,c,id in Equation A1.a).  
 
Multi-stage Modeling Approach 
 
To highlight the tradeoffs associated with different treatment policies (in this case, 
discontinuation), this study was conducted using an integrated, or two-stage, modeling approach. 
While use of integrated modeling approaches has become more visible in the literature, few 
studies have evaluated HIV treatment policy using this method. Earnshaw and colleagues used 
output from a Markov model as inputs to a linear programming model in a resource allocation 
problem applied to diabetes prevention [22]. Brandeau et al. combined an epidemiological model 
and optimization techniques to inform theory regarding resource allocation considerations in 
infectious disease epidemic control [23]. Kim et al. linked a series of state-transition models and 
a binary integer programming model to identify an optimal package of health services in post-
reproductive age women undergoing cervical cancer screening [24]. Kim and Goldie used results 
from a dynamic model as inputs to an individual-level simulation in order to evaluate the cost-
effectiveness of vaccination programs against human papillomavirus (HPV) in young girls [25]. 
Bauch and colleagues approximated dynamic herd immunity effects for a vaccine-preventable 
pediatric infectious disease and applied these effects to a cohort model used to evaluate a 
pediatric vaccination program [26]. Finally, Cleary et al. combined a patient-level state-transition 
model and a linear programming model to assess South African HIV treatment programs, 
comparing a restricted policy (i.e., 1
st
-line ART only) and the current standard of care (1
st
- and 
2
nd
-line ART) [19, 20].  
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SUPPLEMENTARY RESULTS 
 
Internal Validation of the Individual-level Model 
 
Verification of Equilibrium for the Population-level Model 
 
We conducted an analysis that was restricted to a hypothetical steady state (i.e., both 
detected cases and treatment capacity were constant). To produce a steady state, the simulation 
was partitioned into three periods — a burn-in period, analysis period, and censorship period. In 
the burn-in period, cohorts entered the model and individuals initiated and discontinued (due to a 
treatment policy or death) ART until the number of individuals entering and exiting treatment 
from year to year became constant. That is, the burn-in period continued until the model reached 
equilibrium. Once the model reached equilibrium, we used the analysis period to determine the 
optimal strategy or combination of strategies that would maximize life expectancy per member 
of each cohort over a defined timeframe. We also used this period to assess the number of 
individuals receiving treatment. Finally, rather than terminate the analysis at the end of the 
analysis period, we included an additional censorship period to account for the life years that 
would continue to accrue to individuals beyond the analytic timeframe. 
 
 We conducted a series of diagnostic evaluations to ensure that the model had reached a 
steady-state equilibrium. Figures A1 – A3 show three diagnostic and consistency checks for the 
population-level linear programming model. In Figure A1, we assessed percent change in life 
expectancy at the optimum across the periods: burn-in (periods 1–70), analysis (periods 71–80), 
and censorship (periods 81–100) periods. In the analysis period, we found that the percent 
change in life expectancy never exceeded 0·01% across the analysis period. In Figure A2, the 
percent difference at the optimum in the mean number initiating treatment across the analysis 
period remained relatively constant, never varying by more than 0·0008% between periods. 
Finally, Figure A3 shows that, beginning in the analysis period, the number of individuals 
remaining on treatment over time was similar across cohorts. 
 
Sensitivity Analyses 
 
Supplementary selected sensitivity analysis results are shown in Tables A1 – A4. 
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Table A1. Selected sensitivity analysis results: treatment policy and management 
 Treated Individuals Only Treated and Untreated Individuals†  
 
 
 
Strategy* 
 
Life 
Expectancy 
(Years) 
 
Mean Time on 
Treatment 
(Years) 
 
Mean Number 
Initiating Treatment 
Annually 
 
Life 
Expectancy 
(Years) 
 
Total  
Life-Years  
(Years) 
Mean Annual 
Treatment 
Coverage‡ 
(%) 
Number of available ART regimens§ 
One ART regimen available only      
    Status Quo 7·3 6·2 7,090 3·5 530,000 29·4 
    Alternative 6·0 4·1 11,110 3·8 572,000 46·1 
Three ART regimens available     
    Status Quo 9·5 8·0 5,420 3·7 548,000 22·5 
    Alternative 9·0 7·4 5,960 3·7 556,000 24·7 
ART initiation criteria§ 
CD4 count <200 cells/μL     
    Status Quo 8·5 7·0 5,250 3·6 543,000 25·6 
    Alternative 7·7 6·0 6,230 3·7 557,000 30·4 
Patient-level treatment monitoring 
+HIV RNA monitoring¶     
    Status Quo 8·7 7·3 5,950 3·6 542,000 24·7 
    Alternative 7·6 5·4 8,230 3·9 580,000 34·2 
CD4 count decrease 25%║      
    Status Quo 9·0 7·6 5,750 3·6 545,000 23·9 
    Alternative 8·5 6·7 6,590 3·7 561,000 27·4 
Abbreviations:  ART = antiretroviral therapy. 
*  In the Status Quo, antiretroviral therapy (ART) is never discontinued. In the Alternative strategy, ART is discontinued when second-
line ART failure is observed. In the base case, ART failure is defined as a 50% decrease in peak on-treatment CD4 count, CD4 count 
<100 cells/μL, CD4 count below pre-ART nadir, or a WHO stage III/IV event, excluding tuberculosis and severe bacterial infections 
[1].  On average, individuals who received no treatment lived approximately 1·9 years. 
† Results are for a 5-year analytic time horizon for a cohort of 30,000 newly detected infected individuals entering care annually. 
‡ Treatment coverage is defined as the ratio of the number receiving treatment annually to the number qualifying for treatment annually. 
§ In the base case, patients received two sequential ART regimens. ART was initiated at CD4 count <350 cells/μL or a WHO stage 
III/IV event.  
¶ In this sensitivity analysis, both semiannual HIV RNA monitoring and virologic antiretroviral failure criteria (>500 copies/mL) are 
added to the base case monitoring and antiretroviral failure detection assumptions.   
║ In this sensitivity analysis, ART failure is defined defined as a 25% decrease in peak on-treatment CD4 count, CD4 count <100 
cells/μL, CD4 count below pre-ART nadir, or a WHO stage III/IV event, excluding tuberculosis and severe bacterial infections [1]. 
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Table A2. Selected sensitivity analysis results: loss from and return to treatment 
 Treated Individuals Only Treated and Untreated Individuals† 
 
 
 
Strategy* 
 
Life 
Expectancy 
(Years) 
 
Mean Time on 
Treatment 
(Years) 
 
Mean Number 
Initiating Treatment 
Annually 
 
Life 
Expectancy 
(Years) 
 
Total  
Life-Years  
(Years) 
Mean Annual 
Treatment 
Coverage‡ 
(%) 
18-month loss to follow-up§ 
10% increase        
    Status Quo 8·5 7·1 6,170 3·6 550,000 25·9 
    Alternative 7·8 6·0 7,300 3·7 560,000 30·6 
10% decrease       
    Status Quo 9·1 7·9 5,590 3·6 541,000 23·0 
    Alternative 8·3 6·6 6,680 3·7 556,000 27·4 
No loss to follow-up      
    Status Quo 14·7 14·6 3,140 3·4 517,000 11·8 
    Alternative 12·5 11·2 4,130 3·6 537,000 15·4 
Return to care after becoming lost§ 
10% increase       
    Status Quo 8·9 7·5 5,830 3·6 543,000 24·2 
    Alternative 8·1 6·4 6,940 3·7 559,000 28·8 
10% decrease       
    Status Quo 8·7 7·3 5,930 3·6 543,000 24·7 
    Alternative 8·0 6·2 7,040 3·7 558,000 29·3 
No return to care      
    Status Quo 8·0 6·5 6,590 3·6 540,000 27·3 
    Alternative 7·4 5·7 7,650 3·7 553,000 31·8 
*  In the Status Quo, antiretroviral therapy (ART) is never discontinued. In the Alternative strategy, ART is discontinued when second-
line ART failure is observed. In the base case, ART failure is defined as a 50% decrease in peak on-treatment CD4 count, CD4 count 
<100 cells/μL, CD4 count below pre-ART nadir, or a WHO stage III/IV event, excluding tuberculosis and severe bacterial infections 
[1]. On average, individuals who received no treatment lived approximately 1·9 years. 
† Results are for a 5-year analytic time horizon for a cohort of 30,000 newly detected infected individuals entering care annually. 
‡ Treatment coverage is defined as the ratio of the number receiving treatment annually to the number qualifying for treatment annually. 
§ In the base case, 15% were lost from care by 18 months.  We assumed that 50% of those experiencing a WHO stage III/IV event after 
becoming lost would return to treatment and care.  
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Table A3. Selected sensitivity analysis results: antiretroviral efficacy and response to ART 
 Treated Individuals Only Treated and Untreated Individuals†  
 
 
 
Strategy* 
 
Life 
Expectancy 
(Years) 
 
Mean Time on 
Treatment 
(Years) 
 
Mean Number 
Initiating Treatment 
Annually 
 
Life 
Expectancy 
(Years) 
 
Total  
Life-Years  
(Years) 
Mean Annual 
Treatment 
Coverage‡ 
(%) 
2
nd
-line ART effectiveness§ 
10% increase       
    Status Quo 8.9 7.6 5,770 3.6 544,000 24.0 
    Alternative 8.2 6.4 6,830 3.7 559,000 28.4 
10% decrease       
    Status Quo 8·6 7·3 6,000 3.6 542,000 24.9 
    Alternative 7·9 6·2 7,150 3.7 558,000 29.7 
“Late” 2nd-line ART failure§ 
10% increase       
    Status Quo 8·7 7·4 5,930 3·6 543,000 24·6 
    Alternative 8·0 6·3 7,030 3·7 558,000 29·2 
10% decrease       
    Status Quo 8.8 7.5 5,840 3.6 544,000 24.3 
    Alternative 8.1 6.4 6,930 3.7 558,000 28.8 
Independent effect of ART on mortality¶ 
10% increase       
    Status Quo 8·9 7·6 5,790 3·6 544,000 24·0 
    Alternative 8·2 6·4 6,920 3·7 559,000 28·6 
10% decrease       
    Status Quo 8·6 7·3 5,960 3·6 542,000 24·9 
    Alternative 7·9 6·2 7,060 3·7 557,000 29·5 
No independent effect      
    Status Quo 4·5 3·7 10,590 3·3 490,000 52·4 
    Alternative 4·4 3·5 11,210 3·3 498,000 55·5 
Discordant responses among virologically suppressed║ 
19.1% discordant responses**      
    Status Quo 8·3 7·0 6,220 3·6 539,000 26·0 
    Alternative 7·4 5·7 7,720 3·7 556,000 32·2 
10% discordant responses      
    Status Quo 8·6 7·3 5,990 3·6 542,000 24·9 
A4 
    Alternative 7·8 6·1 7,220 3·7 558,000 30·1 
No discordant responses      
    Status Quo 9·0 7·6 5,780 3·6 544,000 24·0 
    Alternative 8·3 6·5 6,760 3·7 559,000 28·0 
Abbreviations:  ART = antiretroviral therapy. 
*  In the Status Quo, antiretroviral therapy (ART) is never discontinued. In the Alternative strategy, ART is discontinued when second-
line ART failure is observed. In the base case, ART failure is defined as a 50% decrease in peak on-treatment CD4 count, CD4 count 
<100 cells/μL, CD4 count below pre-ART nadir, or a WHO stage III/IV event, excluding tuberculosis and severe bacterial infections 
[1]. On average, individuals who received no treatment lived approximately 1·9 years. 
† Results are for a 5-year analytic time horizon for a cohort of 30,000 newly detected infected individuals entering care annually. 
‡ Treatment coverage is defined as the ratio of the number receiving treatment annually to the number qualifying for treatment annually. 
§ Second-line antiretroviral effectiveness refers to 24-week HIV RNA suppression after 2
nd-line ART initiation.  “Late” 2nd-line ART 
failure refers to ART failure after six months on 2nd-line ART.  
¶ Patients with virologic failure but who remain on ART have an independent reduction in AIDS-related mortality compared to those not 
receiving ART [27]. 
║ In the base case, five percent of virologically suppressed patients on ART experienced a discordant response, or no immunologic 
response to ART. 
** Based on data reported in Tuboi JAIDS 2007 [28]. 
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Table A4. Selected sensitivity analysis results: treatment capacity 
 Treated Individuals Only Treated and Untreated Individuals† 
 
 
 
Strategy* 
 
Life 
Expectancy 
(Years) 
 
Mean Time on 
Treatment 
(Years) 
 
Mean Number 
Initiating Treatment 
Annually 
 
Life 
Expectancy 
(Years) 
 
Total  
Life-Years  
(Years) 
Mean Annual 
Treatment 
Coverage‡ 
(%) 
Treatment capacity exceeds treatment demand§ 
10,000 newly detected per year; 50,000 available slots    
    Status Quo 8.8 7.4 5,880 7.0 348,000 73.3 
    Alternative 8.1 6.3 6,980 7.3 363,000 86.9 
Treatment capacity equals treatment demand § 
50,000 newly detected per year; 50,000 available slots    
    Status Quo 8.8 7.4 5,880 3.0 738,000 14.7 
    Alternative 8.1 6.3 6,980 3.0 753,000 17.4 
Treatment demand exceeds treatment capacity§ 
125,000 newly detected per year; 50,000 available slots    
    Status Quo 8.8 7.4 5,880 2.4 1,470,000 5.9 
    Alternative 8.1 6.3 6,980 2.4 1,485,000 7.0 
*  In the Status Quo, antiretroviral therapy (ART) is never discontinued. In the Alternative strategy, ART is discontinued when second-
line ART failure is observed. In the base case, ART failure is defined as a 50% decrease in peak on-treatment CD4 count, CD4 count 
<100 cells/μL, CD4 count below pre-ART nadir, or a WHO stage III/IV event, excluding tuberculosis and severe bacterial infections 
[1]. On average, individuals who received no treatment lived approximately 1·9 years. 
† Results are for a 5-year analytic time horizon for a cohort of 30,000 newly detected infected individuals entering care annually. 
‡ Treatment coverage is defined as the ratio of the number receiving treatment annually to the number qualifying for treatment annually. 
§ In the base case, there were 30,000 newly detected, HIV-infected patients each year and 50,000 total treatment slots available at any 
one time.  
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APPENDIX LEGENDS 
 
Figure A1. Percent change in life expectancy across cohorts, by period of analysis 
The x-axis shows the number of cohorts assessed and the y-axis shows the percent change in life 
expectancy. As the number of cohorts evaluated increased, the percent change in life expectancy 
decreased. #: number. 
 
Figure A2. Average number initiating antiretroviral therapy over time, by period of analysis 
The x-axis shows time (in years); the y-axis shows the number initiating antiretroviral therapy. 
Over time, and as the number of cohorts evaluated increased, the number initiating antiretroviral 
therapy annually became relatively constant. #: number; ART: antiretroviral therapy. 
 
Figure A3. Number of individuals remaining on treatment in previous 10 years, by time period 
The x-axis shows the incident cohort at time t; the y-axis shows the number remaining on 
treatment in each incident cohort. All of the lines in the figure are overlapping, which suggests 
that the number initiating and remaining in care in each analysis period year is constant.  
#: number. 
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Figure A2 
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Figure A3 
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